Autor:	McInerney S; Beatson West of Scotland Cancer Centre, Glasgow, UK., Jones RJ; School of Cancer Sciences, University of Glasgow, Glasgow, UK. Electronic address: robert.jones@glasgow.ac.uk.
Jazyk:	angličtina
Zdroj:	European urology focus [Eur Urol Focus] 2024 Mar; Vol. 10 (2), pp. 222-223. Date of Electronic Publication: 2024 Jun 08.
DOI:	10.1016/j.euf.2024.05.012
Abstrakt:	Enfortumab vedotin and erdafitinib have specific toxicities that need careful management in order to optimise drug exposure while maintaining patients' quality of life. Patient education, meticulous monitoring, and a multidisciplinary approach are key to optimising outcomes so that patients can reap the benefits of these new treatments. (Copyright © 2024 European Association of Urology. Published by Elsevier B.V. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu Full Text from ScienceDirect